Skip to main content
. 2016 Oct 18;12(6):4685–4698. doi: 10.3892/ol.2016.5284

Table IV.

Effect of forbesione on IHC scores for the expression of CK19, PCNA, cyclin A, Bcl-2, Bax, caspase-9 and caspase-3 in allograft tissues.

IHC score

Antigen Groups 0 n (%) 1 n (%) 2 n (%) 3 n (%) 4 n (%) P-value
CK19 Control 0 (0) 0 (0) 1 (25) 1 (25) 2 (50)
Forbesione (50 mg/kg) 0 (0) 1 (25) 2 (50) 1 (25) 0 (0) 0.036a
PCNA Control 0 (0) 0 (0) 1 (25) 3 (75) 0 (0)
Forbesione (50 mg/kg) 0 (0) 2 (50) 2 (50) 0 (0) 0 (0) 0.032a
Cyclin A Control 0 (0) 0 (0) 0 (0) 1 (25) 3 (75)
Forbesione (50 mg/kg) 0 (0) 0 (0) 3 (75) 1 (25) 0 (0) 0.028a
Bcl-2 Control 0 (0) 0 (0) 2 (50) 0 (0) 2 (50)
Forbesione (50 mg/kg) 0 (0) 1 (25) 3 (75) 0 (0) 0 (0) 0.039a
Bax Control 0 (0) 1 (25) 2 (50) 0 (0) 1 (25)
Forbesione (50 mg/kg) 0 (0) 0 (0) 0 (0) 2 (50) 2 (50) 0.039a
Caspase-9 Control 0 (0) 0 (0) 2 (50) 1 (25) 1 (25)
Forbesione (50 mg/kg) 0 (0) 0 (0) 0 (0) 2 (50) 2 (50) 0.028a
Caspase-3 Control 0 (0) 1 (25) 2 (50) 0 (0) 1 (25)
Forbesione (50 mg/kg) 0 (0) 0 (0) 1 (25) 0 (0) 3 (75) 0.039a

The CK19, PCNA, cyclin A, Bcl-2, Bax, caspase-9 and caspase-3 IHC results are represented as follows: 0, completely negative; 1, <25% of CCA area (faint positivity); 2, 25–50% of CCA area (moderate positivity); 3, >50–75% of CCA area (strong positivity); and 4, >75% of CCA area (extremely strong positivity).

a

Significant difference between control and treatment group (P<0.05). IHC, immunohistochemical; CCA, cholangiocarcinoma; CK, cytokeratin; PCNA, proliferating cell nuclear antigen; Bcl, B-cell lymphoma; Bax, Bcl-2-like protein 4.